

Press Information

Secretary of Commerce Pays Visit to Rodos Biotarget

Hannover, 27. August 2015.

On 24 August, 2015, Rodos Biotarget had the honor to host the Secretary of Commerce of the State of Lower Saxony, Germany. Accompanied by a selection of relevant stakeholders from politics, business development and the life sciences, the Secretary acknowledged that “Rodos BioTarget occupies an innovative future field of biotechnology”. Results of the fruitful and constructive exchange will flow into an overall analysis of the increasingly important field of health economy.

Rodos Biotarget is a biopharmaceutical company that joins the ranks of industry leadership in targeted drug delivery. Our proprietary technology, the TARGOSPHERE®, a nanocarrier platform is designed to achieve enhanced prophylactic and therapeutic approaches against diseases of high unmet medical need. Commercialization of our proprietary technology platform is advanced with two in-house therapeutic applications: 1) TARGOBIOTICS™ for the intracellular treatment of bacterial infections, and 2) TARGOVIR™ for the treatment of viral diseases.

In conjunction with the visit, we have revamped and relaunched our web presence. Please visit www.biotargeting.eu. You can navigate the site, both in German and in English.

About Biotarget GmbH

Rodos Biotarget GmbH is a biopharmaceutical company that joins the ranks of industry leadership in nanocarriers for drug delivery. Rodos has developed the versatile TargoSphere® platform technology comprising biocompatible and biodegradable nanocarriers. These are designed to achieve enhanced prophylactic and therapeutic approaches against diseases of high and unmet medical need like cancers, chronic infections, autoimmune diseases, and neurological diseases. Rodos Biotarget offers TargoSphere® to the pharmaceutical industry as a “construction kit”: Specific additives and components of the nanocarriers can be tailored to suit the respective medical objective. The spherical body can be tuned to prolong blood circulation and/or sustained release of the drug payload. Targeting ligands located on the nanocarrier’s surface permit specific delivery of the drug within close proximity to target cells and/or allow for the selective uptake of encapsulated actives into such cells. Rodos nanocarriers aim to improve a drug’s pharmacokinetics, pharmacodynamics, and safety profile, and they also allow for line and label extensions. Rodos pushes the commercialization of its patented technology platform with two in-house therapeutic applications: TargoBiotics™ for the treatment of intracellular bacterial infections, and TargoVir™ for the treatment of devastating viral diseases.

Additional Information: <http://www.biotargeting.eu>

Contact Rodos Biotarget GmbH:

Rodos Biotarget GmbH
Medical Park Hannover
Feodor-Lynen-Str. 23
D-30625 Hannover / FRG
Tel.: +49 (511) 7273 8835
Fax: +49 (511) 214 7076
m.furch@biotargeting.eu